Introduction
Langerhans cell histiocytosis (LCH) is a rare disease mainly seen in children, but it can present at any age.
1,2
The clinical manifestations range from a solitary, asymptomatic osteolytic lesion, called "eosinophilic granuloma", which tends to heal spontaneously, to multiple osteolytic lesions of the skull, intriguingly associated with exophthalmos and diabetes insipidus, formerly called the "Hand-Schuller-Christian" disease.
In addition, in a small proportion of patients, especially toddlers, an ominous form of LCH (once described as the "Abt-Letterer-Siwe" disease) may run an acute course, with dissemination to various organs other than bones (particularly liver and spleen), shaping a multi-system disease as life-threatening as childhood acute lymphoblastic leukemia. Based on solid pathology findings and on a bit of intuition, in 1953 Lichtenstein suggested that these three conditions were part of a common disease spectrum and he coined the term Histiocytosis X: conveying the message that dysregulated proliferation of a histiocytic cell was at the heart of the problem, but that the trigger for this was unknown. 3 The diagnosis of LCH is based on finding in a biopsy, usually of skin or bone, a granuloma consisting of pale histiocytic cells with infolded nuclei, eosinophils and multinucleated giant cells. Staining of the histiocytic cells for CD1a (and CD207 langerin) has become part of the diagnosis (the demonstration by electron microscopy of Birbeck granules is no longer required). 1, 3 The morphology of individual lesions is so uniform as to make it impossible for the pathologist to know whether a biopsy was from a patient with unifocal or with multifocal disease, from a child or from an adult, and whether clinically the disease was indolent or lifethreatening: thus after more than half a century, Lichtenstein's notion is fully vindicated.
Systemic manifestations of LCH
Skin and bone lesions are the most frequent but fortunately the least threatening manifestations of LCH. At the other end of the spectrum, massive liver involvement and dysfunction may lead to rapidly fatal outcome or, sometimes, to late post-inflammatory fibrosis (sclerosing cholangitis). In a minority of these patients liver transplantation may prove curative; but in many the disease reactivates in the transplanted organ. 4 Pulmonary involvement is one of the most puzzling features of LCH. Children may have disseminated interstitial pulmonary nodules and cysts, responsive to systemic therapy. 5 On the other hand, isolated pulmonary LCH is by far the most frequent manifestation in adults. A correlation with cigarette smoking has been clearly
documented. Yet, in most cases smoking cessation is not sufficient to stop the inflammatory process, and these young adults may show progression to multi-cystic metaplasia and become oxygen-dependent. In such patients the role of LCH-directed chemotherapy remains unclear, because existing reports are on small series, and no prospective studies have been conducted. 6 End-stage organ failure often requires lung transplantation, and here too disease recurrence may take place.
Diabetes insipidus (DI), resulting from destruction of the supraoptic-paraventricular nuclei in which vasopressin is produced, 7 hand, based on the concept of an inflammatory disease, anti-inflammatory agents, especially steroids, were used by the British group; although this achieved disease control in most cases, children with chronic/reactivating LCH developed unacceptable side effects of long-lasting steroid exposure. 11 Since the early '90s an international cooperative group of pediatric hematology-oncology specialists met the challenge of conducting three consecutive randomized trials in this "orphan disease". Overall, these studies provided meaningful lessons: 1) In LCH-I comparison of 6-month therapy of vinblastine or etoposide, together with an initial 3-day pulse of prednisone, in all patients with MS-LCH were equivalent with respect to response, survival, disease reactivation, permanent consequences and toxicity. However, early response and prevention of disease reactivation were inferior to results of the more aggressive (five drug combination) and longer (12 months) DAL-HX83/90 protocols, suggesting a need to intensify treatment. 12,13 2) In LCH-II, MS-LCH patients were stratified by risk (high risk being those with age <2 years and/or involvement of "risk organ", i.e. liver, spleen, hematopoietic system, and lung) and randomized to the standard combination of prednisone and vinblastine vs. additional etoposide. In both treatment arms, these patients showed faster disease resolution and a higher survival rate than those in LCH-I, although the 44% reactivation rate was still high.
Lack of advantage, together with its reported leukemogenic potential, caused the discontinuation of study of etoposide in MS-LCH. 14 3) In the successor study, LCH-III, the efficacy of increasing intensity by adding methotrexate in risk organ patients (treated for 12 months) and prolonged initial intense therapy if only partially responding by 6 weeks, was tested but did not provide a better outcome; otherwise, extending the duration of treatment to 12 months proved superior to 6 months in reducing the rate of disease reactivation in children who had achieved disease control. 15 As a result of these trials, the former intuition that patients with LCH should be stratified according to their very different risk of progression and failure, 16 has been validated. Patients with localized disease should be treated conservatively with very limited exceptions; patients with multisystem disease without involvement of vital organs should be treated with the combination of vinblastine and prednisone for a total duration of at least 12 months, which represents the standard of care in pediatric LCH, aiming at limitation of the disease course and thus also of permanent consequences. Yet, additional unmet clinical needs stand in front of us:
about one third of patients who achieve complete control of the disease will suffer relapse during the following months, most often within the same tissue/organ(s) type(s) involved at presentation. Fortunately,
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for this reason the term "reactivation", already proposed since 1982, 16 is now preferred to the term relapse. 17 Beyond disease reactivation, a number of permanent consequences 16 including DI, neurodegeneration, sclerosing cholangitis, pulmonary failure, reduced linear growth and other endocrine dysfunctions, and bone deformities, represent quite a heavy burden for the quality of life of patients cured from LCH. 17, 18 But even more compelling is the remaining minority (20%) of MS-LCH patients --with involvement of liver, spleen, bone marrow --who fail to respond within 2-3 weeks, who still face an unacceptably high risk of early mortality, in the range of 40%. [12] [13] [14] [15] In these patients very intensive chemotherapy, similar to that used for acute myeloid leukemia, turned out to be useful, 19 whereas the role of hematopoietic stem cell transplantation remains uncertain. 20 But definitely this is the subset of patients for whom novel experimental therapies, derived from improved knowledge of LCH pathogenesis, appear warranted.
LCH: inflammatory or neoplastic?
Although in most cases it has only localized manifestations, LCH must be considered a systemic disease.
Unlike leukemia, LCH does not seem to arise from the bone marrow and to spread elsewhere. The basic lesion, the granuloma -the morphology of which was exhaustively described already by 19 th century pathologists -is characteristically enriched in dendritic cells (DC): this is reminiscent of the typical pattern of tissue reaction to an intracellular pathogen, of which the tuberculous granuloma is the prototype. Again it is since the 19 th century that an infectious origin of LCH had been surmised but never proven; and extensive epidemiological studies have failed to identify significant infectious associations. 19 On the other hand, since the early nineties it has been claimed that clonal cell populations are present based on the analysis through an X-linked marker (e.g. the human androgen receptor assay, Humara) of lesional tissue from females with LCH. 22 This finding is per se non conclusive of cancer, since although cancer must be clonal, not every clonal population is cancer: indeed, clonal populations have been observed in benign disorders. Unexplained remission can occur in neoplasm, exceptionally even in widely metastatic cases; but spontaneous healing in LCH is not exceptional: on top of what is frequently seen in skin and bone lesion of children, the provocative observation that some young adult patients with pulmonary LCH remit after smoking cessation is one of the fascinating and incompletely understood features of LCH, suggesting that there may be many pathobiological contributions to the disease process.
The fact that an animal model of LCH has been lacking for a long time has been a forceful stimulus to investigating pathogenesis by ex vivo studies and by looking for bio-markers. Clinical manifestations of LCH -such as aggressive chronic granuloma formation, bone resorption, and soft tissue lesions with occasional neuro-degeneration -show similarities with those observed in other IL-17A-related human diseases (Mycobacterium infection, Crohn's disease, rheumatoid arthritis and multiple sclerosis). In one study peripheral blood samples from patients with LCH were put in culture: the resulting monocyte derived-DC showed extended life-span and propensity to undergo cell fusion leading to the formation of multinucleated giant cells. These features make them excellent candidates to be at the origin of the characteristic granuloma.
Remarkably, both of these properties -extended life-span and propensity to fuse -were reproduced in culture by exposing normal control DCs to interleukin 17A (IL-17A); this phenomenon could be suppressed by exposure to anti-IL17 antibodies, and restored by re-exposure to IL-17A, suggesting an autocrine role for this cytokine with respect to granuloma formation. 23 In the same study, patients with LCH were found to have high levels of IL-17A. However, a second group was unable to detect IL-17A messenger RNA or protein in samples from LCH patients. 24 The authors suggested that the initial finding could be attributed to lack of specificity of the anti-IL17A antibody. Subsequently, this laboratory failed to identify any cells in LCH lesions with IL-17A gene expression, concluding that evidence for IL-17A as a significant factor in LCH had remained inadequate, thus setting a "IL-17 controversy" in LCH. 25 Yet, the DC fusion activity of IL-17A in For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From disease activity. 27 The finding that monocytes play a central role in this process appears to reconcile the controversy and agrees with the recent report of an immature marrow-based dendritic cell of origin in LCH. 28 In spite of much recent progress on LCH that has just been reviewed, there remain three major questions to which we have only partial answers. found that monocyte-derived DC treated with IL-17A express BCL2A1/BFL1, a pro-survival member of the Bcl-2 family. 33 They also proposed that exposure to anti-IL-17A may decrease BFL1 and synergized with chemotherapy to eradicate LCH-DC. 34 Identification of BRAFV600E mutation in 35 of 61 (57%) archived specimens of LCH tissue opened a novel research avenue in LCH. 35 This finding was confirmed by a French group, 36 who yet was unable to document V600E BRAF in peripheral blood cells of patients with LCH, confirming that it is a somatic mutation within the lesional cells. 37 In both studies V600E BRAF did not seem to correlate with age, clinical presentation, or outcome. Yet, those data were not conclusive: (i) only about 40%
of LCH patients have somatic mutations of BRAF; (ii) retroviral transduction of V600E BRAF in myeloid cells resulted in growth arrest and cell death; (iii) in genetically engineered mouse models, V600E BRAF mutation in mature Langerhans cells was insufficient to develop LCH. 38 In a very recent study of 100 LCH lesions, of which 64 carried the V600E BRAF mutation within infiltrating CD207+ DCs, patients with active, high-risk 39 Based on these findings, the authors propose classification of LCH as a myeloid neoplasia. Taking into account this bunch of data, it is tempting to propose a working model for the impairment of transduction pathways driving LCH pathogenic DC development (Figure 2 ).
3. Why do some subjects develop LCH? Studies on familial clustering of the disease had documented that about 1% of patients with LCH have another affected member in the family. When focusing on twin pairs, the rate of concordance is as high as 10% in non-identical twins, and an impressive 92% in identical twins. 40, 41 These data strongly point to a genetic component predisposing to LCH, [40] [41] [42] [43] [44] even though efforts by
Egeler et al. to identify an LCH-associated locus through a genome-wide screening have not been successful. 45 Interestingly, in this study all patients had diploid genomes, which, if anything, casts additional doubt on the neoplastic origin of LCH.
In conclusion, from the clinical point of view LCH is a rare disorder with widely variable manifestations.
After decades in which its pathogenesis remained elusive, recent findings suggest that somatic mutation occurring in a bone marrow myeloid progenitor drive a neoplastic process, while the same somatic mutation occurring at a more differentiated stage drives a self-limiting, inflammatory disorder. The finding of V600E BRAF mutation in all concurrent pulmonary nodules 46 suggests either multiple independent events, or a true spread within the affected lungs. The monocyte/DC plays a pivotal role, and might have been genetically predisposed [40] [41] [42] [43] [44] to becoming over-stimulated by an infectious trigger. Only" pathway, while high GM-CSF concentration (red) can give rise to assembling of CSF2R chains 49 in dodecamer, thus involving the Jak/STAT, Ras/mitogen-activated protein kinase and PI-3 kinase pathways (middle) downstream of Ser 585 and Tyr 577 phosphorylation (red bullet). In IL-17A inflammatory microenvironment (green), Monocyte-derived DC survival can be prolonged for weeks by IL-17A treatment. 33 The TRAF6-dependent IL-17R transduction is able to activate both PI3K / Akt and NF-κB pathways. 48 (B) In LCH patients, while low concentration of GM-CSF will normally induce PI3K / Akt (black), other molecular specificities turn DC survival and phenotype into aggressive myeloid cells: the presence of IL-17A activates both PI3K / Akt and NF-κB pathways (green), leading to increased survival, inflammation and DC fusion. In addition, pathogenic LCH DC express JAG2 and activate transduction downstream of its receptor Notch (brown), 32 which may account for tissue destruction via MMP expression.
V600E
BRAF mutation will ensure constitutive activation of MAPK pathway (red). It would be important in the future to explore the Jak2 / Stat5 pathway which may be absent in LCH DC. From this recent knowledge, new therapeutic interventions in LCH may (i) neutralize IL-17A, (ii) inhibit NOTCH and (iii) V600E BRAF / MAPK pathways and possibly (iv) activate the Jak2 / Stat5 pathway to reverse LCH DC phenotype towards normal DC phenotype as long as we don't understand further the origin of this impairment of DC differentiation.
